Ertapenem for Staphylococcal Sepsis (CERT Trial)

"According to the guidelines set out by this clinical trial, the minimum age requirement for enrollment is 18 years old while the maximum age limit is 100 years old."

"Ertapenem's safety was estimated to be a 2. This is because it is only in Phase 2 trials, meaning that while there are some data supporting its safety, there is currently no evidence of efficacy."

"There are a total of 9 clinical trials underway for Ertapenem. Of these, 2 have reached Phase 3. Most of the research is located in Montreal, Quebec; however, there are 20 different sites running these medical studies."

"Ertapenem can be used to effectively treat moderate, severe complicated intra-abdominal infections, abortion, septic, and moderate, severe community acquired pneumonia (cap)."

"As can be seen on clinicaltrials.gov, this trial is no longer recruiting patients. The last update to the posting was on February 21st, 2022 and the study originally went up on July 1st, 2020. Although this particular trial has finished enrolling patients, there are still 223 other studies that are looking for participants."

"This trial is looking for 60 patients who have staphylococcus aureus septicemia and meet the following criteria: they must be adults over 18 years old, with an unknown MRSA status or a known negative MRSA screening swab within 90 days, and they must be currently receiving cefazolin or it must be clinically appropriate for them to switch to cefazolin. Up to 24 additional hours of open label non-study VANCOMYCIN, LINEZOLID or DAPTOMYCIN may be allowed if there is sepsis and clinical concern for MRSA has not been"

"As of February 21st, 2022, this study is no longer looking for new patients to enrol. This particular clinical trial was posted on July 1st, 2020 but has since been updated. There are currently 214 other trials involving staphylococcus aureus septicemia that are still recruiting and 9 Ertapenem studies also have open enrolment periods."